English

IPO Disclosures

Corporate Governance Financial Information

RHP Audio Visual

Audiovisual Summary

Watch The Audiovisual Summary For A Quick Overview

Legal Disclaimer – Important

NOT FOR ACCESS IN OR BY, OR DISTRIBUTION OR TRANSMISSION IN, INTO OR TO, DIRECTLY OR INDIRECTLY, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS), ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA (THE “UNITED STATES”) OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO.

THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA.

IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the red herring prospectus (“RHP”) and the abridged prospectus (“Abridged Prospectus”) of Manipal Health Enterprises Limited (the “Company”) dated [ 24.07.2026 ], filed with the Registrar of Companies, Karnataka at Bengaluru, Securities and Exchange Board of India (“SEBI”), BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”, together with BSE, the “Stock Exchanges”) hosted on this website in relation to the initial public offering of the equity shares of face value of ₹2 each (“Equity Shares”) of the Company (“Offer”). The Company does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.

Access to the RHP and the Abridged Prospectus does not constitute a recommendation by the Company, any Member of the Syndicate (as defined in the RHP) or any of their respective affiliates or any other person to subscribe to the Equity Shares offered in the Offer.

EACH OF THE RHP AND THE ABRIDGED PROSPECTUS IS BEING MADE AVAILABLE ON THIS WEBSITE IN ELECTRONIC FORM SOLELY TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (“SEBI ICDR REGULATIONS”). The RHP and the Abridged Prospectus have been hosted on this website as prescribed under Regulation 26(1) of the SEBI ICDR Regulations. You are advised to read this disclaimer carefully before reading, accessing or making any other use of the RHP and the Abridged Prospectus. In accessing the RHP and the Abridged Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.

The RHP and the Abridged Prospectus are directed at, and are intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the RHP and the Abridged Prospectus, is not intended for, and may not be accessed in or by, or distributed, published or transmitted in, into or to, directly or indirectly, the United States of America (including its territories and possessions), any state of the United States and the District of Columbia (the “United States”) or any other jurisdiction where it is unlawful to do so. All persons residing outside of the United States who wish to access the RHP and the Abridged Prospectus contained on the following page of this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website or require registration or approval for any acquisition of securities by them. No part of the contents of the RHP and the Abridged Prospectus shall be copied or duplicated in any form by any means or redistributed.

Each of the RHP and the Abridged Prospectus does not constitute an offer to sell, or the solicitation of an offer to purchase or acquire, any securities of the Company in the United States or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws in the United States, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act (“Rule 144A”) and referred to in the RHP and the Abridged Prospectus as “U.S. QIBs”; for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the RHP and the Abridged Prospectus as “QIBs”) in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act, and (ii) outside the United States in “offshore transactions” as defined in, and in compliance with, Regulation S (“Regulation S”) under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. No public offering of the Equity Shares or other securities is being made in the United States.

The RHP and the Abridged Prospectus or any information contained on our website or in the RHP and the Abridged Prospectus do not constitute, and should not be construed as, “general solicitation” or “general advertising” as defined under Regulation D of the U.S. Securities Act, or “directed selling efforts” under Regulation S of the U.S. Securities Act.

The Company and Kotak Mahindra Capital Company Limited, Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, J.P. Morgan India Private Limited, UBS Securities India Private Limited and DBS Bank India Limited, (the “Book Running Lead Managers”) and their respective affiliates, directors, officers, agents, representatives, advisers and employees do not accept any liability whatsoever, direct or indirect, that may arise from the use, interception and interpretation of the information contained on this website. The information in the RHP and the Abridged Prospectus is as of the date thereof and neither the Company, the Promoters, each of the Selling Shareholders, the Book Running Lead Managers nor their respective affiliates, directors, officers, agents, representatives, advisers or employees are under any obligation to update or revise the RHP and the Abridged Prospectus to reflect circumstances arising after the date thereof. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently neither the Company, the Promoters, each of the Selling Shareholders, the Book Running Lead Managers nor any of their respective affiliates, directors, officers, agents, representatives, advisers or employees accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of the RHP and the Abridged Prospectus in electronic format.

Any decision on whether to invest in the Equity Shares described in the RHP and the Abridged Prospectus may only be made solely on the basis of the RHP. Invitations to subscribe to or purchase the Equity Shares in the Offer will be made only pursuant to the RHP if the recipient is in India or the preliminary offering memorandum for the Offer, which comprises the RHP and the preliminary international wrap for the Offer, if the recipient is outside India. No person outside India is eligible to Bid (as defined in the RHP) for Equity Shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which shall contain the selling restrictions for the Offer outside India.

Any potential investor should note that investment in Equity Shares involves a high degree of risk and for details relating to such risk, please see the section titled “Risk Factors” of the RHP.

The Company and the Book Running Lead Managers cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the RHP and the Abridged Prospectus beyond the date of the RHP and the Abridged Prospectus. Neither the Company, the Promoters, each of the Selling Shareholders, the Book Running Lead Managers, nor any of their respective affiliates will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure, disruption, shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into this website, or resulting from the act or omission of any other party involved in producing or hosting this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access or use of the website or these materials.

The information is current only as of its date and shall not, under any circumstances, create any implication that the information contained therein is correct as of any time subsequent to the date thereof or that there has been no change in the financial condition or affairs of the Company since such date. This document may be updated from time to time and there is no undertaking by the Company or any of their affiliates to post any such amendments or supplements on this website.

Please note that application forms downloaded and used for subscription to the Offer in contravention of the above will be rejected with no recourse to the Book Running Lead Managers or the Company or any of their respective affiliates.

Any person into whose possession the RHP and the Abridged Prospectus comes is required to inform himself or herself about and to observe any such restrictions. Investors are advised not to rely on any other document, content or information provided on the Offer on the internet / online websites / social media platforms / micro-blogging platforms and by the influencers since the same is not approved/ commissioned/ paid by the Company or its directors / promoter/ KMPs / SMPs in any manner. Investors are advised to rely only on the information contained in the RHP and the Abridged Prospectus and the price band advertisement for making investment decision.

You are accessing this website at your own risk, and it is your responsibility to take precautions to ensure that it is free from viruses. Neither the Company, the Promoters, each of the Selling Shareholders, the Book Running Lead Managers nor their respective affiliates, directors, officers, agents, representatives, advisers or employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of this website or the RHP and the Abridged Prospectus.

Failure to comply with this disclaimer may result in a violation of the applicable laws of India and other jurisdictions. Any other information contained in, or that can be accessed via our website does not constitute a part of the RHP and the Abridged Prospectus.

IF YOU ARE NOT PERMITTED TO VIEW THE MATERIALS ON THIS WEBSITE OR ARE IN ANY DOUBT AS TO WHETHER YOU ARE PERMITTED TO VIEW THESE MATERIALS, PLEASE EXIT THIS WEBPAGE.

To access this information, you must confirm, by pressing on the button marked “I Confirm”, that at the time of access, you are located in India. If you cannot make this confirmation, you must press the button marked “I Do Not Confirm”.

The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.

I Confirm

Legal Disclaimer – Important

NOT FOR ACCESS IN OR BY, OR DISTRIBUTION OR TRANSMISSION IN, INTO OR TO, DIRECTLY OR INDIRECTLY, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS), ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA (THE “UNITED STATES”) OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO.

THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA.

IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the red herring prospectus (“DRHP”) and the abridged prospectus (“Draft Abridged Prospectus”) of Manipal Health Enterprises Limited (the “Company”) dated [ 24.07.2026 ], filed with the Registrar of Companies, Karnataka at Bengaluru, Securities and Exchange Board of India (“SEBI”), BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”, together with BSE, the “Stock Exchanges”) hosted on this website in relation to the initial public offering of the equity shares of face value of ₹2 each (“Equity Shares”) of the Company (“Offer”). The Company does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.

Access to the DRHP and the Draft Abridged Prospectus does not constitute a recommendation by the Company, any Member of the Syndicate (as defined in the DRHP) or any of their respective affiliates or any other person to subscribe to the Equity Shares offered in the Offer.

EACH OF THE DRHP AND THE DRAFT ABRIDGED PROSPECTUS IS BEING MADE AVAILABLE ON THIS WEBSITE IN ELECTRONIC FORM SOLELY TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (“SEBI ICDR REGULATIONS”). The DRHP and the Draft Abridged Prospectus have been hosted on this website as prescribed under Regulation 26(1) of the SEBI ICDR Regulations. You are advised to read this disclaimer carefully before reading, accessing or making any other use of the DRHP and the Draft Abridged Prospectus. In accessing the DRHP and the Draft Abridged Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.

The DRHP and the Draft Abridged Prospectus are directed at, and are intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the DRHP and the Draft Abridged Prospectus, is not intended for, and may not be accessed in or by, or distributed, published or transmitted in, into or to, directly or indirectly, the United States of America (including its territories and possessions), any state of the United States and the District of Columbia (the “United States”) or any other jurisdiction where it is unlawful to do so. All persons residing outside of the United States who wish to access the DRHP and the Draft Abridged Prospectus contained on the following page of this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website or require registration or approval for any acquisition of securities by them. No part of the contents of the DRHP and the Draft Abridged Prospectus shall be copied or duplicated in any form by any means or redistributed.

Each of the DRHP and the Draft Abridged Prospectus does not constitute an offer to sell, or the solicitation of an offer to purchase or acquire, any securities of the Company in the United States or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws in the United States, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act (“Rule 144A”) and referred to in the DRHP and the Draft Abridged Prospectus as “U.S. QIBs”; for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the DRHP and the Draft Abridged Prospectus as “QIBs”) in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act, and (ii) outside the United States in “offshore transactions” as defined in, and in compliance with, Regulation S (“Regulation S”) under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. No public offering of the Equity Shares or other securities is being made in the United States.

The DRHP and the Draft Abridged Prospectus or any information contained on our website or in the DRHP and the Draft Abridged Prospectus do not constitute, and should not be construed as, “general solicitation” or “general advertising” as defined under Regulation D of the U.S. Securities Act, or “directed selling efforts” under Regulation S of the U.S. Securities Act.

The Company and Kotak Mahindra Capital Company Limited, Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, J.P. Morgan India Private Limited, UBS Securities India Private Limited and DBS Bank India Limited, (the “Book Running Lead Managers”) and their respective affiliates, directors, officers, agents, representatives, advisers and employees do not accept any liability whatsoever, direct or indirect, that may arise from the use, interception and interpretation of the information contained on this website. The information in the DRHP and the Draft Abridged Prospectus is as of the date thereof and neither the Company, the Promoters, each of the Selling Shareholders, the Book Running Lead Managers nor their respective affiliates, directors, officers, agents, representatives, advisers or employees are under any obligation to update or revise the DRHP and the Draft Abridged Prospectus to reflect circumstances arising after the date thereof. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently neither the Company, the Promoters, each of the Selling Shareholders, the Book Running Lead Managers nor any of their respective affiliates, directors, officers, agents, representatives, advisers or employees accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of the DRHP and the Draft Abridged Prospectus in electronic format.

Any decision on whether to invest in the Equity Shares described in the DRHP and the Draft Abridged Prospectus may only be made solely on the basis of the DRHP. Invitations to subscribe to or purchase the Equity Shares in the Offer will be made only pursuant to the DRHP if the recipient is in India or the preliminary offering memorandum for the Offer, which comprises the DRHP and the preliminary international wrap for the Offer, if the recipient is outside India. No person outside India is eligible to Bid (as defined in the DRHP) for Equity Shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which shall contain the selling restrictions for the Offer outside India.

Any potential investor should note that investment in Equity Shares involves a high degree of risk and for details relating to such risk, please see the section titled “Risk Factors” of the DRHP.

The Company and the Book Running Lead Managers cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the DRHP and the Draft Abridged Prospectus beyond the date of the DRHP and the Draft Abridged Prospectus. Neither the Company, the Promoters, each of the Selling Shareholders, the Book Running Lead Managers, nor any of their respective affiliates will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure, disruption, shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into this website, or resulting from the act or omission of any other party involved in producing or hosting this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access or use of the website or these materials.

The information is current only as of its date and shall not, under any circumstances, create any implication that the information contained therein is correct as of any time subsequent to the date thereof or that there has been no change in the financial condition or affairs of the Company since such date. This document may be updated from time to time and there is no undertaking by the Company or any of their affiliates to post any such amendments or supplements on this website.

Please note that application forms downloaded and used for subscription to the Offer in contravention of the above will be rejected with no recourse to the Book Running Lead Managers or the Company or any of their respective affiliates.

Any person into whose possession the DRHP and the Draft Abridged Prospectus comes is required to inform himself or herself about and to observe any such restrictions. Investors are advised not to rely on any other document, content or information provided on the Offer on the internet / online websites / social media platforms / micro-blogging platforms and by the influencers since the same is not approved/ commissioned/ paid by the Company or its directors / promoter/ KMPs / SMPs in any manner. Investors are advised to rely only on the information contained in the DRHP and the Draft Abridged Prospectus and the price band advertisement for making investment decision.

You are accessing this website at your own risk, and it is your responsibility to take precautions to ensure that it is free from viruses. Neither the Company, the Promoters, each of the Selling Shareholders, the Book Running Lead Managers nor their respective affiliates, directors, officers, agents, representatives, advisers or employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of this website or the DRHP and the Draft Abridged Prospectus.

Failure to comply with this disclaimer may result in a violation of the applicable laws of India and other jurisdictions. Any other information contained in, or that can be accessed via our website does not constitute a part of the DRHP and the Draft Abridged Prospectus.

IF YOU ARE NOT PERMITTED TO VIEW THE MATERIALS ON THIS WEBSITE OR ARE IN ANY DOUBT AS TO WHETHER YOU ARE PERMITTED TO VIEW THESE MATERIALS, PLEASE EXIT THIS WEBPAGE.

To access this information, you must confirm, by pressing on the button marked “I Confirm”, that at the time of access, you are located in India. If you cannot make this confirmation, you must press the button marked “I Do Not Confirm”.

The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.

I Confirm

Industry Report

2025-2026

Material Contracts & Material Documents

Agreement dated June 17, 1994 entered into between the Government of West Bengal and Advanced Medicare & Research Institute Limited. Amended and restated brand license agreement dated March 6, 2026 executed between MEMG International India Private Limited and our Company Amended and restated share purchase agreement dated June 21, 2024 entered into by and amongst Polaris Healthcare Investments Pte. Ltd. and our Company. Amendment to the share purchase agreement dated April 5, 2021 Annexure to Consent Letter - Ammar Deed of Adherence -140224 Assurance report dated July 15, 2026 on the compilation of Pro Forma Financial Information. Axis Capital Consent Axis consent Manipal Health Enterprises Proposed.cleaned Brand license agreement dated April 1, 2025 executed between our Company and MH Bengal Brand license agreement dated April 1, 2025 executed between our Company and MH Eastern Brand license agreement dated April 1, 2025 executed between our Company and MHSPL. Brand license agreement dated July 2, 2024 executed between our Company and MHEIPL. Brand license agreement dated October 10, 2022 executed between our Company and MHBPL. Brand license agreement dated October 10, 2022 executed between our Company and MHDPL. Brand license agreement dated October 10, 2022 executed between our Company and MHPL. Canara Consent Cash Escrow and Sponsor Bank Agreement dated July 23, 2026 amongst our Company, each of the Selling Shareholders, the Registrar to the Offer, the BRLMs, the Ban Certificate dated July 23, 2026 issued by Manian & Rao, Chartered Accountants (FRN 001983S), certifying the KPIs of our Company. Certificate dated July 23, 2026 issued by Manian & Rao, Chartered Accountants (FRN 001983S), with respect to average cost of acquisition, weighted average pr Certificate dated July 23, 2026 issued by Manian & Rao, Chartered Accountants (FRN 001983S), with respect to basis for offer price. Certificate dated July 23, 2026 issued by Manian & Rao, Chartered Accountants (FRN 001983S), with respect to employee stock option scheme. Certificate dated July 23, 2026 issued by Manian & Rao, Chartered Accountants (FRN 001983S), with respect to financial indebtedness of our Company and Subsid Certificate dated July 23, 2026 issued by Manian & Rao, Chartered Accountants (FRN 001983S), with respect to outstanding dues to creditors Certificate dated July 23, 2026 issued by Manian & Rao, Chartered Accountants (FRN 001983S), with respect to tax litigation. Certificate of incorporation dated February 15, 2010, issued to our Company, in the name of ‘Manipal Health Enterprises Private Limited’, by the RoC. Certified copies of our AoA Certified copy of our MoA Composite scheme of arrangement for the merger of Manipal Hospitals (Whitefield) Private Limited with our Company, demerger of Jaipur unit Manipal Hospitals Consent dated July 23, 2026 from the Statutory Auditor namely, B S R & Co. LLP, Chartered Accountants Consent Letter - CS and Compliance Officer Consent letter from Ammar Consent letter from Imperius Healthcare Investments Executed Consent letter from Manipal Education and Medical Group India Pvt Ltd Consent letter from Novo Consent letter from Phoenix Consent letter from Seventy Second Investment Company LLC Consent letter from TPG Consent Letter to Mubadala DOA_Executed_(041223) Consent Letter_Dilip Jose Consent Letter_Dr. Ballal Consent Letter_Dr.Ranjan Pai Consent Letter_Puneet Bhatia Consent Letter_Ravi Lambah Consent Letter_Revathy Ashok Consent Letter_Subramaniam Consent Letter_Ved Kalanoria Consent Letter_Vinesh Jairath Consent through certificate dated July 23, 2026 from Aedium Designs Private Limited, architect in respect of certain operational metrics in relation to the h Consent and valid peer review certificate DBS consent Deed of Adherence dated December 12, 2023 entered into between Kabru Investments Pte. Ltd. and Novo Holdings Invest Asia AS. Deed of Adherence dated December 13, 2023 entered into between Kabru Investments Pte. Ltd. and Phoenix Bear Investments, LLC. Deed of Adherence dated February 14, 2024 entered into between Kabru Investments Pte. Ltd. and Ammar Sdn Bhd. Deed of adherence dated July 14, 2026 entered into between TPG SG Magazine Pte. Ltd. and MRMSI and deed of adherence entered into between our Company and MEM Deed of Adherence dated July 18, 2023 entered into between TPG SG Magazine Pte. Ltd. and our Company. Deed of Adherence dated November 25, 2023 entered into between Kabru Investments Pte. Ltd. and Seventy Second Investment Company LLC. Due diligence certificate dated March 23, 2026 addressed to SEBI from the BRLMs. Examination report, dated July 15, 2026 on our Restated Consolidated Financial Information; Explainatory statement to Shareholders’ resolution dated March 10, 2026, approving the Fresh Issue and other related matters Final observation letter bearing number 1154182026 dated July 3, 2026 issued by SEBI First Amendment Agreement dated March 6, 2026 entered into amongst our Company, Kabru Investments Pte. Ltd., Kangto Investments Pte. Ltd., Imperius Healthcar Fresh certificate of incorporation dated December 24, 2025, issued to our Company, in the name of ‘Manipal Health Enterprises Limited’, by the Registrar of HDFC LETTER MANIPAL consent IBL Consent Letter In-principle listing approvals each dated June 9, 2026, issued by BSE In-principle listing approvals each dated June 9, 2026, issued by NSE Inter-se agreement dated April 6, 2023 executed amongst Kangto Investments Pte. Ltd., Kabru Investments Pte. Ltd., Imperius Healthcare Investments Pte. Ltd., Inter-se agreement dated January 7, 2024 entered into between TPG SG Magazine Pte. Ltd. and Novo Holdings Invest Asia AS. Inter-se agreement dated January 7, 2024 entered into between TPG SG Magazine Pte. Ltd. and Phoenix Bear Investments, LLC. IP Certificate JP Morgan- Consent KFinTech Kotak Mahindra Kotak Signed_Consent_letter Liberty - LW Consent (July 23 2026) LOI to the Registrar Agreement dated March 23, 2026, MANIPAL002.cleaned Medical professional services agreement dated April 1, 2025 entered into between our Company and Dr. Hebri Sudarshan Ballal read with the addendum dated 1 Medical professional services agreement dated April 1, 2025 entered into between our Company and Dr. Hebri Sudarshan Ballal read with the addendum dated 2 Medical professional services agreement dated April 1, 2025 entered into between our Company and Dr. Hebri Sudarshan Ballal read with the addendum dated 3 Medical professional services agreement dated April 1, 2025 entered into between our Company and Dr. Hebri Sudarshan Ballal read with the addendum dated 4 MHE Consol signed Audit report FY25 MHEL Consol FS and AR Mar 2026 MHEL Standalone FS and AR Mar 2026 MHEL_BR- Approval of IPO - 04.03.2026 MHEL_BM_Taking on record SS OFS-23.03.2026 MHEPL CFS Signed FS MHEPL FS & Audit Report - March 2025-standalone MHEPL Standalone Signed FS MHEPL-Directpr report -24-25-signed MHEPL_Directors Report_2023-24_Signed Monitoring Agency Agreement dated July 15, 2026 entered into between our Company and the Monitoring Agency. MRMSI read with the termination agreement dated March 18, 2026. Offer Agreement dated March 23, 2026, entered into amongst our Company, each of the Selling Shareholders and the BRLMs. Peer review certificate from auditor Project Liberty - Consent letter from Bankers to the Offer (005) Project Liberty - Consent letter from the BRLMs_Executed_RHP Project Liberty- CAM Consent Letter Registrar Agreement dated March 23, 2026, entered into amongst our Company, each of the Selling Shareholders and the Registrar to the Offer. Report dated July 23, 2026 on the statement of possible special tax benefits available to the Company, its shareholders, and its material subsidiaries Report titled “Assessment of healthcare delivery sector in India” dated July, 2026, prepared and issued by CRISIL Intelligence which has been exclusively com Resolution dated July 23, 2026, passed by the Audit Committee approving the KPIs for disclosure Resolution of the Board of Directors dated July 23, 2026 taking on record the approval for the Offer for Sale by the Selling Shareholders. Share Escrow Agreement dated July 20, 2026 amongst each of the Selling Shareholders, our Company and the Share Escrow Agent. Syndicate Agreement dated July 23, 2026 amongst our Company, each of the Selling Shareholders, Registrar to the Offer, the BRLMs and Syndicate Member. Syndicate member consent UBS consent Project Peak - Share Purchase Agreement [Executed 9 July 2025].cleaned 13. Sahyadri Hospital Pvt Ltd Valuation Report Project Tacoma 2 - SPA - Executed - 30 Oct Tacoma 2_SPA Amendment Agreement (April 5 2021) 15. Final Valuation Report - Columbia_September 30 16. MHJPL & MHDPL - Manipal Valuation Report_Signed_13.01.22 17.Ares - Amendment Agreement to the PA - Executed Version 17.Ares - Deed of Adherence MHPL - Executed Version 17.Ares - Purchase Agreement - Executed Version 18.MH(E)IPL - FEMA Valuation Report - 28.08.2023 20. Omnifin signed Report Medica Synergie FEMA May 24 21.Udaan - SPA (Multiples Mauritius) - Executed 2Jun2021 (1) 22.Udaan - SPA (Multiples India) - Executed 2Jun2021 23. HBPL - FEMA Valuation Report - 01 June 2021 - Signed 24.MHSB_ Share Purchase Agreement dtd 7.4.2021.stamped 26.ii)Scheme of Arrangement_Demerger 27.Project Wisdom - Scheme (Updated) - 21-08-2023 28. Valuation report 29.484551830_Scheme of Demerger 30. IDPL- Valuation Report_Igen - 31.03.2022 2.14.16 26.Valuation Report Manipal Vijaywada 5th Jan 2017 32.Medcis RD merger order.cleaned 2.1.10.1.1.1 1. Project Liberty - Shareholders Agreement dated 6 April 2023 41. Second Amendment Agreement (Executed).cleaned 42. Deed of Adherence - Executed - 1July2024 42. Lisbon - SHA - 3 September 2021 (executed) 43. First Amendment to SHA 43._Share Subscription Agreement (Executed Version) 44.Healthmap_Shareholders_ Agreement 44.Share Subscription Agreement (SSA)_compressed 46.Project Liberty - Restated Inter Se Agreement (Executed Copy) 5. Explainatory statement-10-03-2026 5. MHEL-EGM_Approval of IPO-10.03.2026 MHEL_BM_Approving the DRHP-23.03.2026 60. Consent letter BSR Final_Signed Axis Bank Project Liberty - Consent letter_KMBL 65. JPMorgan Consent 65. UBS consent GS_Consent Jefferies Consnet Kotak consent AXIS 667190112_MHEL_102BM_RHP Approval - 23-07-2026 MHPL_NSDL- Signed TPA Tripartile Agreement-MHEPL Signed-NSDL 79. Tripartite Agreement_MHEPL- CDSL MHPL_CDSL_Tripartite-Agreement-Signed

Price Band

You’re on Our Indian Website

Visit the Global site for International patient services

Need Assistance?
'Click' to chat with us
Chat with us